NZ584454A - N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases - Google Patents

N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases

Info

Publication number
NZ584454A
NZ584454A NZ584454A NZ58445408A NZ584454A NZ 584454 A NZ584454 A NZ 584454A NZ 584454 A NZ584454 A NZ 584454A NZ 58445408 A NZ58445408 A NZ 58445408A NZ 584454 A NZ584454 A NZ 584454A
Authority
NZ
New Zealand
Prior art keywords
4alkyl
alkyl
6alkyl
compound
methoxy
Prior art date
Application number
NZ584454A
Other languages
English (en)
Inventor
Hans Allgeier
Martin Augustin
Anke Mueller
Lutz Zeitlmann
Andreas Marquardt
Michael A Pleiss
Original Assignee
Ingenium Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenium Pharmaceuticals Gmbh filed Critical Ingenium Pharmaceuticals Gmbh
Publication of NZ584454A publication Critical patent/NZ584454A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ584454A 2007-10-12 2008-10-13 N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases NZ584454A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99882107P 2007-10-12 2007-10-12
PCT/EP2008/063715 WO2009047359A1 (en) 2007-10-12 2008-10-13 Inhibitors of protein kinases

Publications (1)

Publication Number Publication Date
NZ584454A true NZ584454A (en) 2011-09-30

Family

ID=40227837

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ584454A NZ584454A (en) 2007-10-12 2008-10-13 N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases

Country Status (19)

Country Link
US (2) US8716296B2 (enExample)
EP (1) EP2212297B1 (enExample)
JP (2) JP5681855B2 (enExample)
KR (1) KR20100090772A (enExample)
CN (2) CN101889004B (enExample)
AT (1) ATE510827T1 (enExample)
AU (1) AU2008309517B2 (enExample)
BR (1) BRPI0818543A2 (enExample)
CA (1) CA2702008A1 (enExample)
DK (1) DK2212297T3 (enExample)
EA (1) EA020439B1 (enExample)
HK (1) HK1203950A1 (enExample)
HR (1) HRP20110470T1 (enExample)
IL (1) IL204594A (enExample)
MX (1) MX2010003987A (enExample)
NZ (1) NZ584454A (enExample)
SI (1) SI2212297T1 (enExample)
WO (1) WO2009047359A1 (enExample)
ZA (1) ZA201001910B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2539568C2 (ru) 2008-10-31 2015-01-20 Дженентек, Инк. Пиразолопиримидиновые соединения-ингибиторы jak и способы
WO2010053861A2 (en) * 2008-11-07 2010-05-14 H. Lundbeck A/S Biologically active amides
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
EP2544686A4 (en) 2010-02-05 2013-06-26 Whitehead Biomedical Inst COMBINATION PROCEDURE FOR THE TREATMENT OF A DISEASE
SG183192A1 (en) 2010-03-10 2012-09-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
JP2013107824A (ja) * 2010-03-17 2013-06-06 Dainippon Sumitomo Pharma Co Ltd 新規単環ピリミジン誘導体
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
KR101995013B1 (ko) * 2010-07-13 2019-07-02 에프. 호프만-라 로슈 아게 Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
US20130303507A1 (en) * 2011-01-28 2013-11-14 Novartis Ag Substituted hetero-biaryl compounds and their uses
EP2561867A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
EP2562265A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Susceptibility to selective CDK9 inhibitors
WO2013052417A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
IN2014KN02601A (enExample) 2012-04-24 2015-05-08 Vertex Pharma
RU2014145121A (ru) 2012-05-22 2016-07-10 Зэ Юниверсити Оф Норд Каролина Эт Чапел Хилл Пиримидиновые соединения для лечения злокачественной опухоли
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
SMT202100687T1 (it) 2013-03-12 2022-01-10 Vertex Pharma Inibitori della dna-pk
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
BR112015023013A2 (pt) 2013-03-13 2017-07-18 Abbvie Inc inibidores de quinase cdk9
US9073922B2 (en) 2013-03-14 2015-07-07 Abbvie, Inc. Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
US9796708B2 (en) 2013-03-14 2017-10-24 Abbvie Inc. Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
CN105189512A (zh) 2013-03-14 2015-12-23 艾伯维公司 吡咯并嘧啶cdk9激酶抑制剂
GB2513403A (en) * 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
ES2705342T3 (es) 2013-10-17 2019-03-22 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
US9328112B2 (en) 2014-02-06 2016-05-03 Abbvie Inc. Tetracyclic CDK9 kinase inhibitors
WO2015157122A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
PE20211782A1 (es) 2014-05-23 2021-09-08 Hoffmann La Roche Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
DK3539961T3 (da) 2015-06-29 2022-01-03 Astrazeneca Ab Polycykliske amidderivativer som cdk9-inhibitorer
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
JP6954921B2 (ja) 2016-04-07 2021-10-27 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としてのピリジル誘導体
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
EP3804724B1 (en) * 2016-10-20 2022-12-07 Pfizer Inc. Cdk inhibitors for treating pah
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
MX388257B (es) 2017-05-18 2025-03-19 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2.
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
RU2769696C2 (ru) 2017-05-22 2022-04-05 Ф. Хоффманн-Ля Рош Аг Терапевтические соединения и композиции и способы их применения
US11149021B2 (en) * 2017-05-24 2021-10-19 Abbisko Therapeutics Co., Ltd. N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
CA3159628A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Mrgprx2 antagonists and uses thereof
AU2020401999B2 (en) 2019-12-09 2024-01-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
RU2754441C2 (ru) * 2019-12-30 2021-09-02 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
WO2022197756A1 (en) * 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Plasma kallikrein inhibitors
WO2022257965A1 (zh) * 2021-06-09 2022-12-15 石药集团中奇制药技术（石家庄）有限公司 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
CN115703760B (zh) * 2021-08-11 2024-05-31 山东大学 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用
CN115703738B (zh) * 2021-08-16 2024-06-21 中国科学院上海药物研究所 含2-芳杂环取代的脲类化合物、其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100521735B1 (ko) 2000-02-25 2005-10-17 에프. 호프만-라 로슈 아게 아데노신 수용체 조절인자
DE10114138C2 (de) 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
DE10129028A1 (de) 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
US20040106647A1 (en) 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20060293339A1 (en) 2003-03-24 2006-12-28 Chakravarty Prasun K Biaryl substituted 6-membered heterocycles as sodium channel blockers
GB0315966D0 (en) 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
AU2004261482A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2005040135A1 (ja) 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. 抗ストレス薬およびその医薬用途
WO2005103022A1 (en) 2004-04-20 2005-11-03 Transtech Pharma, Inc. Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
FR2878247B1 (fr) 2004-11-19 2008-10-03 Galderma Res & Dev Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
EP1901747A2 (en) * 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain

Also Published As

Publication number Publication date
DK2212297T3 (da) 2011-09-05
US8716296B2 (en) 2014-05-06
IL204594A0 (en) 2010-11-30
EA201000554A1 (ru) 2011-04-29
ATE510827T1 (de) 2011-06-15
EP2212297B1 (en) 2011-05-25
CN101889004A (zh) 2010-11-17
AU2008309517A1 (en) 2009-04-16
US20100249149A1 (en) 2010-09-30
EA020439B1 (ru) 2014-11-28
MX2010003987A (es) 2010-08-04
AU2008309517B2 (en) 2013-03-14
IL204594A (en) 2013-12-31
HRP20110470T1 (hr) 2011-07-31
CA2702008A1 (en) 2009-04-16
HK1203950A1 (en) 2015-11-06
ZA201001910B (en) 2011-05-25
KR20100090772A (ko) 2010-08-17
US20150038516A1 (en) 2015-02-05
BRPI0818543A2 (pt) 2018-10-23
JP5681855B2 (ja) 2015-03-11
WO2009047359A1 (en) 2009-04-16
EP2212297A1 (en) 2010-08-04
HK1150052A1 (en) 2011-10-28
CN101889004B (zh) 2014-09-10
JP2011500539A (ja) 2011-01-06
CN104151293A (zh) 2014-11-19
SI2212297T1 (sl) 2011-09-30
JP2015038077A (ja) 2015-02-26

Similar Documents

Publication Publication Date Title
EP2212297B1 (en) Inhibitors of protein kinases
US8436007B2 (en) Inhibitors of protein kinases
US9067888B2 (en) Inhibitors of protein kinases
EP2137166B1 (en) 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
US20150011576A1 (en) Inhibitors of Protein Kinases
WO2008129069A1 (en) Inhibitors of protein kinases
US8507511B2 (en) Inhibitors of protein kinases
EP2137163B1 (en) Inhibitors of protein kinases
HK1150052B (en) Inhibitors of protein kinases
EP2137164A1 (en) Inhibitors of protein kinases
HK1179623B (en) Inhibitors of protein kinases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: ASTRAZENECA AB, SE

Effective date: 20140410

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2016 BY CPA GLOBAL

Effective date: 20150904

LAPS Patent lapsed